This page has tags:

1. 1 2016-08-18T06:50:05-07:00 Ken Londoner 67400b6d41c00fbf11f194dad77d72364b87b2e2 Media Files Ken Londoner 3 Tag: Media Files vistag 2017-02-17T05:41:53-08:00 Ken Londoner 67400b6d41c00fbf11f194dad77d72364b87b2e2

This page is referenced by:

• 1 2021-08-17T00:34:58-07:00 Atrial Fibrillation 1 plain 2021-08-17T00:34:59-07:00 What is an arrhythmia?
  
  Arrhythmia (or dysrhythmia) are abnormal heart rhythms that can cause the heart to pump less efficiently.
  Ken Londoner, CEO of BioSig Tech explains that under normal conditions, as the electrical impulse moves through the heart, it contracts between 60 and 100 times per minute. Each contraction represents one beat. The atria contract a fraction of a second before the ventricles so that the blood they contain is emptied into the ventricles before the ventricles contract.
  Under certain conditions, almost all of the heart tissue is capable of starting a beat, or becoming the pacemaker. An arrhythmia occurs when:
  • The heart's natural pacemaker produces an abnormal rate or rhythm.
  • The normal conduction pathway is disrupted.
  • Another part of the heart takes on the role of a pacemaker.
  
  What is the electrocardiogram (ECG)?
  
  The electrical activity of the heart is measured by an electrocardiogram (ECG or EKG). By placing electrodes at specific locations on the body (chest, arms, and legs), a graphical representation or tracing of electrical activity can be obtained. Changes in a normal traced ECG can indicate arrhythmias as well as other heart-related conditions. Ken Londoner and his team at BioSig Tech has developed a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, enabling electrophysiologists to see more signals, and analyze them in real-time. The platform is called PURE EP™ and brings together a range of proprietary hardware and software into a single platform. Its low-noise architecture, large dynamic range, and high frequency bandwidth accurately capture the full range of cardiac signals with high fidelity, while customizable software modules and filters enable unlimited real-time analysis.
  
  
  What is atrial fibrillation?
  
  Atrial fibrillation, also called atrial fibrillation, is a type of arrhythmia. In atrial fibrillation the electrical signals from the atria (the two small chambers of the heart) are sent in a very fast and uncontrolled way. The atria vibrate instead of contracting. Electrical signals reach the ventricles in an irregular way. When the atria do not contract effectively, blood can pool or clot. If a clot lodges in an artery in the brain, a stroke can occur. About 15 percent of strokes occur in people with atrial fibrillation.
  
  Ken Londoner indicates that the PURE EP platform is designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
  According to Ken Londoner, aspirin, warfarin, and other heart medications can be used to treat atrial fibrillation.
  
   
• 1 2017-02-17T05:41:07-08:00 New Tech Can Help Treat Atrial Fibrillation 1 plain 2017-02-17T05:41:08-08:00 For many years scientists have been looking to come up with less invasive procedures to treat Atrial Fibrillation and get better outcomes. Finally it seems that all that hard work has paid off, as we’re on the edge of discovering something big. Not long ago, when medications for irregular heart rate of atrial fibrillation failed to heal, surgery was the only treatment left. But thanks to the latest cutting edge research in this field assisted by people like Ken Londoner, doctors are finally given more options which don't involve cutting or stitching, and more importantly have quicker recovery process than surgery.
  
  
  
  New emerging areas of research and innovation around mapping systems can allow cardiologists to see the source of atrial fibrillation, and target the areas of the heart muscle that are causing the problems. If this new technology can help reveal the source, than doctors will only have to focus on the misfiring areas, and hence increase the success rates dramatically. Starting from 2009, Ken Londoner has been leading BioSig Technologies, a medical device company that is developing technology platforms designed to improve and assist electrophysiologists. According to analysts’ forecasts, the global market for EP devices will grow from $2.5 billion in 2012 to $5.5 billion by 2019, and thus it will become one of the fastest growing medical device segments.
  
  In order to achieve advances in catheter ablation, medical device companies like the one founded by Londoner, are putting their trust and money in 3-D imaging which can hopefully help target the right areas for treatment. Although this technology has been around for a long time, experts say that now they will take 3-D technology to the next level and will not only see anatomy in 3-D, but they'll also be able to see the propagation of the electrical waves in 3-D. As executive chairman and director of BioSig, Ken Londoner has invested a lot in this emerging technology and is planning to move forward, hoping that complications can be reduced to less than 1 percent, which is a  major improvement.